GPC Draws $10M Up Front In Japanese Marketing Deal June 26, 2007 One month away from an FDA panel review, GPC Biotech Inc.'s satraplatin for prostate cancer has become the subject of a $10 million license deal with Yakult Honsha Co. Ltd., for rights in Japan. (BioWorld Today)Read More
RSS